BridgeBio Pharma, Inc. (BBIO): R&D Expense
$451.95M
Year ended 2025-12-31
$505.38M
Trailing 12 months to 2026-06-30
+4.2%
3-year compound annual growth
+6.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $451.95M | -10.8% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $506.46M | +11.1% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $455.71M | +14.1% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $399.46M | -11.4% | 2025-02-20, From 2022-01-01 |
| 2021-12-31 | $451.02M | +33.8% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $337.05M | +60.5% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $209.95M | +49.9% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $140.07M | +358.4% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $30.56M | n/a | 2020-03-03, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $451.95M | -10.8% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $206.01M | -5.3% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $186.18M | +32.4% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $148.29M | -30.1% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $220.90M | -5.8% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $44.54M | -11.4% |
| Insmed Inc (INSM) | 2025-12-31 | $771.09M | +28.9% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $124.03M | +17.9% |
Compare BBIO, TVTX, MIRM, NATR side by side · Screen every company in Pharmaceutical Preparations ↗